Genentech Articles
Stock Commentary - Europe
23 May 2005
Stock Commentary - New York
23 May 2005
Promotions at Genentech
16 May 2005
Amgen/Abigenix' panitumumab enters Ph III
16 May 2005
Stock Commentary - New York
9 May 2005
Biogen: 1st-qtr profit despite Tysabri loss
9 May 2005
R&M reviews Roche position, future
9 May 2005
Tarceva sNDA filed with US FDA
9 May 2005
ImmunoGen, Genentech extend collaboration
9 May 2005
Stock Commentary - New York
28 April 2005
Herceptin to become a blockbuster drug?
27 April 2005
Stock Commentary - New York
25 April 2005
Stock Commentary - Europe
25 April 2005
Strong data for Roche/Genentech/Biogen Idec's MabThera
25 April 2005
Roche 1st-qtr sales, up 17%, beat estimates
25 April 2005
Tysabri shows strong results as add-on MS therapy
25 April 2005
Curis gets extra $2.0M from Genentech
25 April 2005
Genentech and Array BioPharma expand research accord
18 April 2005
UPDATE: Roche's Rituxan shows improvement in RA
18 April 2005
Immunomedics' anti-CD20 Ab effective for severe lupus
18 April 2005
Roche's MabThera to treat RA?
11 April 2005
Japan stock market week to April 4
11 April 2005
Curis and Genentech enter 2nd major deal
11 April 2005
Are cancer drug costs leaving benefits behind?
11 April 2005
Stock Commentary - New York
28 March 2005
Genentech and Ipsen add to existing accord
28 March 2005
Stock Commentary - Europe
28 March 2005
Appointments at Encysive
28 March 2005
Roche's cancer drug Avastin debuts in UK
21 March 2005
Xenova's full-year 2004 loss cut as costs plunge
14 March 2005
IMS: 2004 world Rx sales growth slowest in six yrs
14 March 2005
Rx safety fears are an opportunity for biotech to educate Congress and public: BIO meeting
7 March 2005
Raptiva effective long-term in psoriasis
28 February 2005
OXiGENE's CA4p boosts efficacy of Avastin
21 February 2005
Studies show benefit of Xolair in asthma
21 February 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Biogen Idec boosted by Avonex
14 February 2005
Positive trial results for Sanofi-Aventis
7 February 2005
Stock Commentary - New York
7 February 2005
Benefit of Eloxatin chemo plus Avastin
7 February 2005
Positive trial results for Sanofi-Aventis
7 February 2005
Roche disappoints despite 116% net income hike
7 February 2005
Novartis shows off strong R&D pipeline at annual conference
31 January 2005
New product launches in 2004
31 January 2005
Corixa and Genentech sign license agreement
24 January 2005
Stock Commentary - New York
24 January 2005
Stock Commentary - Europe
24 January 2005
UPDATE: Roche's Avastin cleared in Europe
24 January 2005
Stock Commentary - New York
17 January 2005
Editor's views on biotech; clinical trial transparency
17 January 2005
FDA clears Avastin's updated safety label
17 January 2005
Avastin cleared for cancer in Switzerland
10 January 2005
Roche's MabThera improves survival in NHL at 30 months
20 December 2004
Xencor and Genentech in antibody deal
13 December 2004
Roche's Genentech gamble pays off
13 December 2004
BioMarin's 3rd-qtr net loss widens
22 November 2004
Organizational changes at Genentech
22 November 2004
Genentech and Rinat to co-develop pain Ab
15 November 2004
US CMS cover for off-label cancer drug use
15 November 2004
US drug market CAGR "set to slow to 9.7%"
15 November 2004
Xenova sees first nine months sales slide
15 November 2004
UK industry figure slams lack of drug access
8 November 2004
Biogen's 3rd-qtr profit falls on merger costs
8 November 2004
Raptiva launched in UK for psoriasis
8 November 2004
Roche's Avastin on track in EU
1 November 2004
New cancer drug costs too high for some?
25 October 2004
Genentech gets subpoena on Rituxan
11 October 2004
Xolair "inflammation compound of the year"
11 October 2004
Genentech extends stock repurchase
4 October 2004
Celera and Genentech in oncology deal
4 October 2004
Genentech and Wyeth in manufacturing accord
4 October 2004
Serono's Raptiva Oked for psoriasis in EU
4 October 2004
New Phase III results indicate versatility of Tarceva in treating range of cancers
27 September 2004
Genentech fights for stock option valuation
20 September 2004
Innovative drugs and their impact on the future of oncology developments
20 September 2004
In August, biotech emerges from doldrums, but uncertainty persists: Burrill review
13 September 2004
Tarceva filed in EU for advanced NSCL cancer
30 August 2004
Stock Commentary - Europe
23 August 2004
Stock Commentary - New York
23 August 2004
Genentech's Avastin linked to serious blood clots
23 August 2004
Xenova's loss dips for first-half 2004
23 August 2004
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
